BHC

Bausch Health Companies Inc. (BHC) | Rumor.io

Bausch Health Companies

BHC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,141

Bullish sentiment (50-day avg)84%

Price to earnings ratio13.3

Market capitalization2.2B

Earnings per share-2.94

Dividend yield (TTM)69.2%

Revenue (annual)10.3B

Net income (annual)120M

Social

What share of all stock conversation is about BHC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 24

Bausch Health Companies Inc. is mentioned in a discussion about presumptuous arbitrage, but the author notes that the company's math behind its valuation is unclear.
An update is provided on the Larsucosterol trial, now in 86 locations with 21 currently recruiting, as of August 24, 2028.
The ticker symbol $BHC is expected to reach $8.

Generated by AI

Sentiment

Of the messages about BHC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	85.71% +8.79	81.16% -13.59
Bearish	—	—	14.29% -8.79	18.84% +13.59

Bullish· Jul 31

The company has experienced a 50% increase in value after a successful call, with the author attributing the success to the call-maker.
The stock has broken out and is trading above the 200 Day Moving Average, with the author expecting the stock to continue its upward trend.
The company's recent earnings beat and raised guidance have led to a significant increase in value, with the author noting a 53.8% jump in just five days and a strong options action.

Bearish· Aug 2

Bausch Health Companies Inc. ($BHC) faces significant debt maturities in 2027-2028, raising concerns about its solvency.
The company's reliance on Xifaxan, which is losing exclusivity in January 2028, is a major concern for its long-term solvency.
Piper Sandler downgraded BHC to Underweight with a price target of $3, citing concerns about the company's ability to execute on its plan and prove its solvency to the market.

Generated by AI

Topics

Of the messages about BHC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	16.67%	5.29%
Announcements	—	—	0%	16.41%
Analysts	—	—	0%	4.74%
Macro	—	—	83.33%	3.96%
Earnings	—	—	0%	9.8%
Controversies	—	—	0%	59.8%

Earnings· Aug 9

Bausch Health Companies Inc. ($BHC) reported Q2 2022 earnings of $0.55 per share, missing the consensus estimate of $0.89.
The company's revenue of $1.97B also missed expectations, with a guidance cut to $8.05B-$8.22B for FY 2022.
BHC's debt reduction of $0.5B over the last quarter was a positive note amidst the disappointing earnings announcement.

Analysts· Sep 17

Bausch Health Companies Inc. ($BHC) was upgraded to neutral by Bank of America Securities, with a price target of $19.00.
The upgrade is based on a balanced risk/reward assessment, but the spin timeline could be protracted.
Analysts are very confident about $BHC, with a buy consensus of 86% based on analysis by 13 analysts.

Announcements· Dec 1

Bausch Health Companies Inc. ($BHC) has completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., expanding Solta Medical's geographical reach and market scale in China.
The acquisition provides Solta Medical with an enhanced ability to address increasing market demand for aesthetics treatments through localized solutions and proven technologies.
Thomas J. Appio, Chief Executive Officer of Bausch Health, stated that the acquisition expands Solta Medical's geographical reach and market scale in China, and will drive future revenue and market share growth.

Controversies· Sep 9

Bausch Health Companies Inc. is mentioned alongside Valeant, another company exposed by short seller Mr. Left, who is now facing a criminal charge.
Mr. Left's firm claims to have helped expose fraud at over 50 companies, including Valeant, raising questions about the motivations behind the authorities' action against him.
Mr. Dorsey, a financial writer, notes that Mr. Left's case is unusual given his history of uncovering corporate wrongdoing, including at Valeant.

Technical Analysis· Mar 15

$BHC is in a downtrend, with the MACD histogram turning negative.
This indicator suggests a potential decline in the stock's price.
The post views the MACD histogram as a significant indicator for $BHC's performance.

Generated by AI

Community

Of the messages about BHC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	64.29%	31.95%
Newcomers	—	—	35.71%	68.05%

Regulars· Jul 31

The BHC stock price is experiencing a significant upswing, with some regulars discussing potential breakout confirmations and others expressing surprise at the continued upward momentum.
The company's Larsucosterol trial has received Breakthrough Therapy Designation from the FDA, and some regulars are speculating about the potential indications and future conference calls.
The stock's volume is high, with some regulars noting 5 million shares traded and others discussing the possibility of a large block buyer.

Newcomers· Aug 24

The newcomer is questioning why Cohen hasn't provided clear math behind the proposed deal, implying a desire for more transparent financial information.
The newcomer is drawing a comparison to Valeant's offer for Allergan in 2014, suggesting a familiarity with past M&A deals and a desire for similar financial clarity.
The newcomer is anticipating financial clarity closer to earnings, implying an interest in the company's financial performance and potential deal timing.

Generated by AI

On September 8, Bausch Health Companies Inc. (NYSE:BHC) and Belgian skincare innovator YUN announced they are extending their microbiome-focused dermatology partnership into Mexico and five additional markets spanning Central and Eastern Europe and Central Asia. The move builds on a 2025 launch in Poland and lands just weeks after the company raised its full-year guidance […]

14d agoYahoo! Finance Canada

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

21d agotheglobeandmail.com

Bausch Health Expands Collaboration With Yun

Bausch Health (BHC) said Tuesday it expanded its collaboration with biotech firm Yun to expand acces

22d agoYahoo Finance

Bausch Health launches Fraxel FTX laser system in Australia

28d agoInvesting.com

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning September 1, 2026.

29d agoYahoo Finance

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program. Since launching in 2013, the program has awarded 87 scholarships, totaling over $1 million, to students who have been treated for dermatologic conditions. This year, six inspiring students will each receive up to $10,000 to support their undergraduate or graduate studies.

1mo agoYahoo Finance

Also Discussed

Investors talking about BHC also mention

#	Name	Attention
1	Bausch + Lomb CorporationBLCO	0%0
2	Perrigo Company plcPRGO	0%0
3	Herbalife Ltd.HLF	0%new
4	iShares Biotechnology ETFIBB	0.01%0
5	Teva Pharmaceutical Industries Ltd. ADRTEVA	0%0
6	PGIM Short Duration High Yield ETFPSH	0%new
7	SUNation Energy Inc.SUNE	0%new
8	Under Armour Inc.UAA	0%0
9	Gilead Sciences, Inc.GILD	0%-0.04
10	Pacer MSCI World Industry Advantage ETFGLBL	0%0

Bausch Health Companies Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company focused on developing, manufacturing, and marketing healthcare products across multiple therapeutic areas. Bausch Health serves the gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health markets, with a portfolio that includes branded, generic, and over-the-counter medicines as well as medical devices. Its operations are organized around products and services used in treating conditions such as digestive disorders, skin diseases, neurological conditions, and vision-related care. The company also supports hospital and clinic needs through its medical device and ophthalmic businesses. Headquartered in Laval, Quebec, Bausch Health plays a significant role in the global healthcare market by supplying therapies and devices used by patients, physicians, and healthcare providers across the United States and international markets.

Website

Location

2150 St. Elzéar Blvd. West

Laval, QC, H7L 4A8

Canada

Social

What share of all stock conversation is about BHC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 24

Bausch Health Companies Inc. is mentioned in a discussion about presumptuous arbitrage, but the author notes that the company's math behind its valuation is unclear.
An update is provided on the Larsucosterol trial, now in 86 locations with 21 currently recruiting, as of August 24, 2028.
The ticker symbol $BHC is expected to reach $8.

Generated by AI

Sentiment

Of the messages about BHC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	85.71% +8.79	81.16% -13.59
Bearish	—	—	14.29% -8.79	18.84% +13.59

Bullish· Jul 31

The company has experienced a 50% increase in value after a successful call, with the author attributing the success to the call-maker.
The stock has broken out and is trading above the 200 Day Moving Average, with the author expecting the stock to continue its upward trend.
The company's recent earnings beat and raised guidance have led to a significant increase in value, with the author noting a 53.8% jump in just five days and a strong options action.

Bearish· Aug 2

Bausch Health Companies Inc. ($BHC) faces significant debt maturities in 2027-2028, raising concerns about its solvency.
The company's reliance on Xifaxan, which is losing exclusivity in January 2028, is a major concern for its long-term solvency.
Piper Sandler downgraded BHC to Underweight with a price target of $3, citing concerns about the company's ability to execute on its plan and prove its solvency to the market.

Generated by AI

Topics

Of the messages about BHC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	16.67%	5.29%
Announcements	—	—	0%	16.41%
Analysts	—	—	0%	4.74%
Macro	—	—	83.33%	3.96%
Earnings	—	—	0%	9.8%
Controversies	—	—	0%	59.8%

Earnings· Aug 9

Bausch Health Companies Inc. ($BHC) reported Q2 2022 earnings of $0.55 per share, missing the consensus estimate of $0.89.
The company's revenue of $1.97B also missed expectations, with a guidance cut to $8.05B-$8.22B for FY 2022.
BHC's debt reduction of $0.5B over the last quarter was a positive note amidst the disappointing earnings announcement.

Analysts· Sep 17

Bausch Health Companies Inc. ($BHC) was upgraded to neutral by Bank of America Securities, with a price target of $19.00.
The upgrade is based on a balanced risk/reward assessment, but the spin timeline could be protracted.
Analysts are very confident about $BHC, with a buy consensus of 86% based on analysis by 13 analysts.

Announcements· Dec 1

Bausch Health Companies Inc. ($BHC) has completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., expanding Solta Medical's geographical reach and market scale in China.
The acquisition provides Solta Medical with an enhanced ability to address increasing market demand for aesthetics treatments through localized solutions and proven technologies.
Thomas J. Appio, Chief Executive Officer of Bausch Health, stated that the acquisition expands Solta Medical's geographical reach and market scale in China, and will drive future revenue and market share growth.

Controversies· Sep 9

Bausch Health Companies Inc. is mentioned alongside Valeant, another company exposed by short seller Mr. Left, who is now facing a criminal charge.
Mr. Left's firm claims to have helped expose fraud at over 50 companies, including Valeant, raising questions about the motivations behind the authorities' action against him.
Mr. Dorsey, a financial writer, notes that Mr. Left's case is unusual given his history of uncovering corporate wrongdoing, including at Valeant.

Technical Analysis· Mar 15

$BHC is in a downtrend, with the MACD histogram turning negative.
This indicator suggests a potential decline in the stock's price.
The post views the MACD histogram as a significant indicator for $BHC's performance.

Generated by AI

Community

Of the messages about BHC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	64.29%	31.95%
Newcomers	—	—	35.71%	68.05%

Regulars· Jul 31

The BHC stock price is experiencing a significant upswing, with some regulars discussing potential breakout confirmations and others expressing surprise at the continued upward momentum.
The company's Larsucosterol trial has received Breakthrough Therapy Designation from the FDA, and some regulars are speculating about the potential indications and future conference calls.
The stock's volume is high, with some regulars noting 5 million shares traded and others discussing the possibility of a large block buyer.

Newcomers· Aug 24

The newcomer is questioning why Cohen hasn't provided clear math behind the proposed deal, implying a desire for more transparent financial information.
The newcomer is drawing a comparison to Valeant's offer for Allergan in 2014, suggesting a familiarity with past M&A deals and a desire for similar financial clarity.
The newcomer is anticipating financial clarity closer to earnings, implying an interest in the company's financial performance and potential deal timing.

Generated by AI

Bausch Health Companies

Social

Aug 24

Bullish· Jul 31

Bearish· Aug 2

Earnings· Aug 9

Analysts· Sep 17

Announcements· Dec 1

Controversies· Sep 9

Technical Analysis· Mar 15

Regulars· Jul 31

Newcomers· Aug 24

Bausch Health (BHC) Expands Probiotic Skincare Bet To Six New Markets

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Bausch Health Expands Collaboration With Yun

Bausch Health launches Fraxel FTX laser system in Australia

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

Also Discussed

Bausch Health Companies Inc.

Company Information

Location

Bausch Health (BHC) Expands Probiotic Skincare Bet To Six New Markets

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Bausch Health Expands Collaboration With Yun

Bausch Health launches Fraxel FTX laser system in Australia

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

Also Discussed

Social

Aug 24

Bullish· Jul 31

Bearish· Aug 2

Earnings· Aug 9

Analysts· Sep 17

Announcements· Dec 1

Controversies· Sep 9

Technical Analysis· Mar 15

Regulars· Jul 31

Newcomers· Aug 24